Lilly Sees Basaglar Sales Begin To Slide
Insulin Glargine Product Sees A Reversal In Q3, Although Nine-Month Sales Still Up
Eli Lilly has seen its Basaglar insulin glargine product suffer a slide in the third quarter of 2020, representing a reversal after a period of growth that has led to a recent plateau. However, nine-month sales were still up on the same period last year.
You may also be interested in...
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.